Maravai LifeSciences Holdings Inc
NASDAQ:MRVI

Watchlist Manager
Maravai LifeSciences Holdings Inc Logo
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Watchlist
Price: 5.22 USD 5.24% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Maravai LifeSciences Holdings Inc?
Write Note

Maravai LifeSciences Holdings Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Maravai LifeSciences Holdings Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
PP&E Net
$222.6m
CAGR 3-Years
30%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
PP&E Net
$9.4B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
PP&E Net
$6B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
11%
Mettler-Toledo International Inc
NYSE:MTD
PP&E Net
$790.4m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
PP&E Net
$1.6B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
4%
IQVIA Holdings Inc
NYSE:IQV
PP&E Net
$772m
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
15%
No Stocks Found

Maravai LifeSciences Holdings Inc
Glance View

Market Cap
1.3B USD
Industry
Life Sciences Tools & Services

Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 470 full-time employees. The company went IPO on 2020-11-20. The firm provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The firm's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The company also provides research products for labeling and detecting proteins in cells and tissue samples. Its products include CleanCap, messenger ribonucleic acid (mRNA) and oligonucleotide. The Biologics Safety Testing focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing spectrum. The firm provides ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.

MRVI Intrinsic Value
3.79 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Maravai LifeSciences Holdings Inc's PP&E Net?
PP&E Net
222.6m USD

Based on the financial report for Dec 31, 2023, Maravai LifeSciences Holdings Inc's PP&E Net amounts to 222.6m USD.

What is Maravai LifeSciences Holdings Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
39%

Over the last year, the PP&E Net growth was 91%. The average annual PP&E Net growth rates for Maravai LifeSciences Holdings Inc have been 30% over the past three years , 39% over the past five years .

Back to Top